Overview HFSRT With Concurrent TMZ for Large BMs Status: Recruiting Trial end date: 2022-12-03 Target enrollment: Participant gender: Summary A multi-center randomized phase III trial was conducted to investigate the feasibility and safety of adding temozolomide to hypofractionated stereotactic radiotherapy for large brain metastases. Phase: Phase 3 Details Lead Sponsor: Chinese Academy of Medical SciencesTreatments: DacarbazineTemozolomide